MARKET

OCUL

OCUL

Ocular
NASDAQ

Real-time Quotes | Nasdaq Last Sale

14.55
+0.14
+0.97%
Opening 12:15 06/24 EDT
OPEN
14.46
PREV CLOSE
14.41
HIGH
14.77
LOW
14.37
VOLUME
217.19K
TURNOVER
--
52 WEEK HIGH
24.30
52 WEEK LOW
7.14
MARKET CAP
1.11B
P/E (TTM)
-6.3905
1D
5D
1M
3M
1Y
5Y
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers
Benzinga · 06/08 20:48
Ocular Therapeutix™ to Participate at Three Upcoming Investor Conferences
Ocular Therapeutix, Inc. (Nasdaq: OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will participate at the following con...
Business Wire · 05/26 12:00
Insider Trends: Ocular Therapeutix Insider Extends 90-Day Selling Trend
MT Newswires · 05/21 21:12
Global Retinal Drugs and Biologics Market Statistics, Cagr, Outlook, And Covid-19 Impact 2021 - 2023
May 12, 2021 (Heraldkeepers) -- The Retinal Drugs and Biologics market report provides a detailed analysis of global market size, regional and country-level...
Heraldkeepers · 05/12 10:56
Ocular Sealants and Glues Market Opportunities, Growth and Forecasting for next Upcoming Year Until 2029 | Ocular Therapeutix Inc., Johnson & Johnson, Reliance Life-Sciences & so on…
May 10, 2021 (MARKITWIRED via COMTEX) -- Future Market Insights (FMI) adopted a multidisciplinary approach during the pandemic-era to focus on the growth and...
Markitwired · 05/10 07:19
Sustained Release Ocular Drug Delivery Systems Market Growth Opportunities, Key Driving Factors, Market Scenario and Forecast 2021 - 2028 By Ameco Research
pune, India, Mon, 10 May 2021 00:04:22 / Comserve Inc. / -- The global Sustained Release Ocular Drug Delivery Systems market is segmented by company, region...
Comserve · 05/10 04:07
--Berenberg Bank Adjusts Ocular Therapeutix PT to $26 From $27, Maintains Buy Rating
MT Newswires · 05/07 11:19
Ocular Therapeutix (OCUL) Receives a Rating Update from a Top Analyst
In a report released today, Yi Chen from H.C. Wainwright reiterated a Hold rating on Ocular Therapeutix (OCUL). The company's shares closed last Thursday
SmarterAnalyst · 05/07 10:47
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of OCUL. Analyze the recent business situations of Ocular through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average OCUL stock price target is 25.33 with a high estimate of 30.00 and a low estimate of 15.00.
EPS
Institutional Holdings
Institutions: 187
Institutional Holdings: 50.16M
% Owned: 65.75%
Shares Outstanding: 76.29M
TypeInstitutionsShares
Increased
54
3.60M
New
25
967.95K
Decreased
45
4.46M
Sold Out
18
3.25M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.87%
Pharmaceuticals & Medical Research
+1.11%
Key Executives
Non-Executive Chairman/Independent Director
Charles Warden
President/Chief Executive Officer/Director
Antony Mattessich
Chief Financial Officer
Donald Notman
Corporate Executive
Michael Goldstein
Senior Vice President
Rabia Ozden
General Counsel
Philip Strassburger
Independent Director
Jeffrey Heier
Independent Director
Seung Suh Hong
Independent Director
Richard Lindstrom
Independent Director
Bruce Peacock
Independent Director
Leslie Williams
Independent Director
Suh Hong Seung
No Data
About OCUL
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development, manufacturing and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Its lead product candidate, DEXTENZA (dexamethasone insert) for intracanalicular use, has completed Phase III clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. OTX-TP (travoprost insert) is in Phase III clinical development for glaucoma and ocular hypertension. Its earlier stage assets include OTX-TIC, a sustained release travoprost intracameral injection for the treatment of moderate to severe glaucoma and ocular hypertension, as well as sustained release intravitreal injections for the treatment of retinal diseases. These injections include the development of OTX-TKI, a tyrosine kinase inhibitor, and, in collaboration with Regeneron an extended release protein-based anti-vascular endothelial growth factor trap.

Webull offers kinds of Ocular Therapeutix Inc stock information, including NASDAQ:OCUL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OCUL stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading OCUL stock methods without spending real money on the virtual paper trading platform.